<DOC>
	<DOC>NCT01078220</DOC>
	<brief_summary>This is a post-licensure safety surveillance program to detect potential safety signals in subjects, from the managed care organizations database, who have used GARDASIL™.</brief_summary>
	<brief_title>Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)</brief_title>
	<detailed_description />
	<mesh_term>Papillomavirus Infections</mesh_term>
	<criteria>3Dose Safety Population Female 926 years at the time of first dose of GARDASIL™ Completed the 3dose regimen of GARDASIL™ per protocol Pregnancy Safety Population Received at least one dose of GARDASIL™ up to 30 days prior to the date of conception or any time between conception and the day of pregnancy resolution Autoimmune Safety Population Female who has received at least one dose of GARDASIL™ Has been a member of same Managed Care Organization (MCO) for at least 12 months prior to the receipt of GARDASIL™ Any Dose Safety Population Female who has received at least one dose of GARDASIL™ 3Dose Safety Population Male Receives incomplete regimen of GARDASIL™ Completes the three dose regimen of GARDASIL™ in more than 12 months Less than 28 day interval between doses 1 and 2 or less than a 12 week interval between doses 2 and 3 Younger than 9 or older than 26 years of age at receipt of first dose Pregnancy Safety Population Males No record of pregnancy at the Managed Care Organization (MCO) Autoimmune Safety Population Member of the same MCO for less than 12 months prior to receiving the first dose Male</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Human Papillomavirus (HPV)</keyword>
</DOC>